bioAffinity Technologies, Inc. — Regulatory Filings 2022

Aug 25, 2022

CORRESP 1 filename1.htm

VIA EDGAR CORRESPONDENCE

August 25, 2022

United States Securities and Exchange Commission

Office of Trade & Services

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Ms. Taylor Beech

Re:
Registration
Statement on Form S-1, File No. 333-264463
Registration
Statement on Form 8-A, File No. 001-41463
WITHDRAWAL
OF REQUEST FOR ACCELERATION OF EFFECTIVENESS

Dear Ms. Beech:

Reference is made to a letter filed by bioAffinity Technologies, Inc. (the “Company”) as correspondence via EDGAR on August 24, 2022, in which the Company requested that the effectiveness of the above-captioned Registration Statements on Form S-1, as amended, and Form 8-A, as amended, be accelerated to 4:30 p.m., Eastern Daylight Time, on Thursday, August 25, 2022, in accordance with Rule 461 under the Securities Act of 1933, as amended.

The Company is no longer requesting that such Registration Statements be declared effective at this time and hereby formally withdraws its requests for acceleration of that effective date.

If you have any questions regarding this withdrawal, please contact the Company’s outside counsel, Wilhelm E. Liebmann of Dykema Gossett PLLC at (210) 554-5414.

| Very
truly yours, | |
| --- | --- |
| BIOAFFINITY
TECHNOLOGIES, INC. | |
| By: | /s/
Maria Zannes |
| Name: | Maria
Zannes |
| Title: | Chief
Executive Officer |

Field: Page; Sequence: 1; Options: Last

Field: /Page